Mesoblast Limited (MESO) Financials
MESO Assets vs Liabilities
| Date | Assets | Liabilities |
|---|---|---|
| June 30, 2026 | 773.1 million | 204.7 million |
| March 31, 2026 | 773.1 million | 204.7 million |
| Dec. 31, 2025 | 782.3 million | 207.6 million |
| Sept. 30, 2025 | 782.3 million | 207.6 million |
MESO Free Cash Flow and Stock based compensation
Graph available only for paid members. Upgrade to see it.
| Date | Free Cash Flow | Stock based compensation |
|---|---|---|
| June 30, 2026 | -6.9 million | 2.9 million |
| March 31, 2026 | -4.5 million | ? |
| Dec. 31, 2025 | -15.7 million | ? |
| Sept. 30, 2025 | -15.3 million | ? |
MESO Net Income
No data available :(
MESO Cash and Debt
Graph available only for paid members. Upgrade to see it.
| Date | Cash | Debt | Capital Lease |
|---|---|---|---|
| June 30, 2026 | 102.9 million | 108.6 million | 8.1 million |
| March 31, 2026 | 102.9 million | 108.6 million | 8.1 million |
| Dec. 31, 2025 | 129.6 million | 60.1 million | 8.3 million |
| Sept. 30, 2025 | 130.0 million | 60.1 million | 8.3 million |
MESO Shares Outstanding
MESO Expenses
Graph available only for paid members. Upgrade to see it.
| Date | Capex | R&D | G&A | S&M |
|---|---|---|---|---|
| June 30, 2026 | 205500 | 25.7 million | 14.4 million | - |
| March 31, 2026 | 352000 | 25.7 million | 14.4 million | - |
| Dec. 31, 2025 | 133000 | 23.1 million | 14.3 million | - |
| Sept. 30, 2025 | 349000 | 23.1 million | 14.3 million | - |
MESO Cost of Revenue
Graph available only for paid members. Upgrade to see it.
| Date | Revenue | Cost of Revenue |
|---|---|---|
| June 30, 2026 | 35.0 million | -49.4 million |
| March 31, 2026 | 34.5 million | 14.9 million |
| Dec. 31, 2025 | 25.7 million | 26.9 million |
| Sept. 30, 2025 | 25.7 million | 26.9 million |
MESO
Price: $13.87
52 week price:
Earnings Per Share: -0.44 USD
Exchange: NMS
Sector: Healthcare
Industry: Biotechnology
Country: Australia
Volume: 45251
Ebitda: -19.5 millionMarket Capitalization: 1.8 billion